MARC record from Internet Archive

LEADER: 08585cam 2200829Ia 4500
001 ocn324998244
003 OCoLC
005 20200514232328.0
008 090518s2005 paua ob 001 0 eng d
006 m o d
007 cr cn|||||||||
040 $aOPELS$beng$epn$cOPELS$dOPELS$dOCLCQ$dDMJ$dOCLCQ$dOCLCF$dOCLCE$dOCLCO$dCHVBK$dOCLCQ$dYDXCP$dOCLCQ$dOCLCA$dKIJ$dOCLCQ$dOCLCO$dOCLCA
019 $a489077447$a607595824$a607765312$a974616725$a974671140$a988554722$a1027345100$a1113433415$a1119398829
020 $a9781437713015
020 $a1437713017
020 $a9780721602585
020 $a0721602584
035 $a(OCoLC)324998244$z(OCoLC)489077447$z(OCoLC)607595824$z(OCoLC)607765312$z(OCoLC)974616725$z(OCoLC)974671140$z(OCoLC)988554722$z(OCoLC)1027345100$z(OCoLC)1113433415$z(OCoLC)1119398829
037 $a179287:175649$bElsevier Science & Technology$nhttp://www.sciencedirect.com
042 $adlr
050 4 $aRC685.H8$bH76783 2005
060 4 $a2005 E-845
060 4 $aWG 340$bH99426 2005
082 04 $a616.1/32$222
084 $a44.85$2bcl
245 00 $aHypertension :$ba companion to Brenner and Rector's the kidney /$c[edited by] Suzanne Oparil, Michael A. Weber.
250 $a2nd ed.
260 $aPhiladelphia :$bElsevier Mosby,$c℗♭2005.
300 $a1 online resource (xxv, 872 pages) :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
500 $aCompanion v. to Brenner & Rector's the kidney / edited by Barry M. Brenner. 7th ed. c2004.
504 $aIncludes bibliographical references and index.
505 0 $aSect. 1. Background and history. A history of hypertension treatment -- The National High Blood Pressure Education Program -- Epidemiology of hypertension -- sect. 2. Pathophysiology. Pathophysiology of hypertension -- Blood pressure genetics -- The sympathetic nervous system in acute and chronic blood pressure elevation -- Environmental and psychosocial stress in hypertension onset and progression -- Renin -- Angiotensin-converting enzymes: properties and function -- Angiotensin-(1-7) -- The angiotensin receptors: AT ́and AT ́-- Aldosterone and mineralocorticoids -- The role of insulin resistance and compensatory hyperinsulinemia in patients with essential hypertension -- Remodeling of resistance arteries in hypertension -- Clinical applications of arterial stiffness in hypertension -- Endothelium in hypertension: nitric oxide.
505 0 $aEndothelin in hypertension -- Natriuretic peptides -- Vasodilator peptides: CGRP, substance P, and adrenomedullin -- The Kallikrein-Kinin System as a regulator of cardiovascular and renal function -- sect. 3. Target organ damage/cardiovascular events. The concept of total risk -- New interpretations of blood pressure: the importance of pulse pressure -- Coronary atherosclerotic sequelae of hypertension -- Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension -- Renal protection in chronic kidney disease -- sect. 4. Diagnosis. Initial evaluation and follow-up assessment -- Prognostic and diagnostic value of ambulatory blood pressure monitoring -- White-coat hypertension -- sect. 5. Treatment: general considerations. The blood pressure lowering treatment trialists' collaboration (BPLTTC).
505 0 $aThe antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) -- The LIFE study -- The VALUE trial -- Main results from VALUE -- Clinical outcome trials of hypertension with angiotensin receptor blockers -- ACE inhibitor trials: effects in hypertension -- Critical assessment of hypertension guidelines -- Current prescribing practices -- Calcium channel blockers: controversies, lessons, and outcomes -- Nursing clinics in the management of hypertension -- Community outreach -- Medication adherence for antihypertensive therapy -- sect. 6. Diet and nutrition. Diet: micronutrients -- Dietary approaches to hypertension management: the DASH studies -- Obesity and hypertension: impact on the cardiovascular and renal systems -- Alcohol and hypertension -- Obesity in hypertension: the role of diet and drugs -- Exercise and hypertension.
505 0 $aSect. 7. Pharmacologic treatment. Initial choices in the treatment of hypertension -- Pharmacokinetics of antihypertensive drugs -- Fixed combination antihypertensive therapy -- Chronotherapeutics in the treatment of hypertension -- sect. 8. Comorbid conditions and special populations in hypertension. Diabetes mellitus and the cardiovascular metabolic syndrome: reducing cardiovascular and renal events -- Hypertension in patients on renal replacement therapy -- Ischemic heart disease in hypertension -- Hypertension in the elderly -- Management of hypertension in Black populations -- Hypertension in pregnancy -- Hypertension in children -- Resistant hypertension -- Orthostatic hypotension and autonomic dysfunction syndromes.
505 0 $aSect. 9. Individual drug classes. How antihypertensive drugs get approved in the United States -- Diuretics: mechanisms of action -- [beta]-adrenergic blockers -- [alpha]-adrenoceptor blockers -- Angiotensin-converting enzyme inhibitors -- Calcium antagonists -- Angiotensin II receptor antagonists -- Direct-acting smooth muscle vasodilators and adrenergic inhibitors -- Endothelin antagonists -- Mineralocorticoid receptor antagonists -- Vasopeptidase inhibitors -- Renin inhibitors -- sect. 10. Secondary hypertension. Obstructive sleep apnea and hypertension -- Renovascular hypertension: diagnosis and treatment -- Adrenal cortex hypertension -- Phoechromocytoa: detection and management -- Anesthesia and hypertension -- Management of hypertensive emergencies and urgencies -- Aggressive blood pressure targets; developing effective algorithms.
520 $aThe revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Today's leading experts discuss all aspects of the field--from pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications. Assesses the risks of specific pharmacological treatments * offers expert analysis of recent clinical trials * and providesDelivers strategies for managing patients with comorbid conditions such as diabetes, renal disease, and ischemic heart disease. Explains the role of vascular biology in the pathogenesis of hypertension.
588 0 $aPrint version record.
506 $3Use copy$fRestrictions unspecified$2star$5MiAaHDL
533 $aElectronic reproduction.$b[S.l.] :$cHathiTrust Digital Library,$d2010.$5MiAaHDL
538 $aMaster and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.$uhttp://purl.oclc.org/DLF/benchrepro0212$5MiAaHDL
583 1 $adigitized$c2010$hHathiTrust Digital Library$lcommitted to preserve$2pda$5MiAaHDL
650 0 $aHypertension.
650 12 $aHypertension$xtherapy.
650 22 $aAntihypertensive Agents$xtherapeutic use.
650 22 $aHypertension$xcomplications.
650 22 $aHypertension$xphysiopathology.
650 22 $aLife Style.
650 7 $aHypertension.$2fast$0(OCoLC)fst00965831
650 17 $aHypertensie.$2gtt
650 7 $aHipertensa o (farmacologia;tratamento)$2larpcal
650 7 $aCardiopatias.$2larpcal
655 4 $aElectronic books.
700 1 $aOparil, Suzanne.
700 1 $aWeber, Michael A.,$d1942-
730 0 $aBrenner & Rector's the kidney.
776 08 $iPrint version:$tHypertension.$b2nd ed.$dPhiladelphia : Elsevier Mosby, ℗♭2005$z0721602584$z9780721602585$w(DLC) 2004051303$w(OCoLC)56567478
856 40 $3Google$uhttp://books.google.com/books?id=_gxsAAAAMAAJ
856 40 $3HathiTrust Digital Library, Limited view (search only)$uhttp://catalog.hathitrust.org/api/volumes/oclc/56567478.html
856 40 $3ScienceDirect$uhttp://www.sciencedirect.com/science/book/9780721602585
856 40 $3ScienceDirect$uhttp://www.mdconsult.com/public/book/view?title=Oparil+&+Weber:+Hypertension$zAn electronic book accessible through the World Wide Web; click for information
938 $aYBP Library Services$bYANK$n12233505
029 1 $aCHBIS$b007226840
029 1 $aCHVBK$b18187458X
029 1 $aDEBBG$bBV042310540
029 1 $aDEBSZ$b407388729
029 1 $aNZ1$b15192491
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 135 OTHER HOLDINGS